Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?

Company Overview - Zoetis (ZTS) is expected to report flat earnings of $1.40 per share for the quarter ended December 2025, with revenues projected at $2.37 billion, reflecting a 2.1% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - A positive Earnings ESP of +0.84% suggests that analysts are optimistic about Zoetis's earnings prospects, although the company holds a Zacks Rank of 3 [12]. Historical Performance - In the last reported quarter, Zoetis exceeded the expected earnings of $1.62 per share by delivering $1.70, resulting in a surprise of +4.94% [13]. - Over the past four quarters, Zoetis has consistently beaten consensus EPS estimates [14]. Industry Context - In comparison, Neurocrine Biosciences (NBIX) is expected to post earnings of $2.25 per share for the same quarter, marking a significant year-over-year increase of +125%, with revenues anticipated to rise by 25% to $784.42 million [18].